Medical Cannabis and PTSD in Veterans: What the Research Currently Shows
Last Updated: February 2026 | Reading Time: 4 minutes
Post-traumatic stress disorder affects a significant portion of Canadian veterans and Canadian Armed Forces members. As rates of medical cannabis authorization have increased in this population, researchers have begun examining what the evidence actually shows — and where important distinctions lie.
This article summarizes peer-reviewed findings on medical cannabis and PTSD in Canadian and international veteran populations. It does not constitute clinical advice and should not be read as a recommendation for any individual.
What Canadian Research Has Found
A 2023 cross-sectional study published in BMC Psychiatry (St. Cyr, Nazarov, Le et al.) examined 415 Canadian Armed Forces members and veterans attending a specialized mental health outpatient clinic in Ontario between 2018 and 2020. The study documented both the prevalence and the correlates of cannabis use in this population: 45.1% reported current cannabis use for medical or recreational purposes, despite the absence of clinical practice guidelines addressing it. The statistically significant correlates of use were younger age, lower income, hazardous alcohol use, and increased bodily pain — notably, PTSD severity was not significantly associated with cannabis use status in this sample, which the authors attribute in part to the treatment-seeking nature of the cohort.
A 2025 cross-sectional study in the Journal of Veterans Studies (Sheehy, Storey, Rash, Tippin, Parihar & Harris) examined 513 Canadian veterans living with chronic pain and a history of trauma. The study investigated whether cannabis use characteristics — prescription status, route of administration, THC:CBD ratio, grams per day — were associated with differences in PTSD outcomes. Cannabis use characteristics were not significantly correlated with PTSD severity in Sheehy et al.’s own data. However, the paper reviewed a body of prior literature in which a clinically important distinction has been observed: recreational cannabis use was associated with worsening PTSD outcomes in some studies, while medicinal use — obtained through authorized channels — was associated with improved outcomes. On a self-reported perceived-benefit basis, 76% of cannabis-using participants in the Sheehy study described cannabis as helpful for PTSD, and 92% described it as helpful for sleep.
Treatment-Resistant Veterans: International Evidence
A 2023 retrospective study published in Frontiers in Psychiatry (Nacasch, Avni & Toren) followed 14 combat veterans with treatment-resistant PTSD — patients who had not responded to standard pharmacological or psychotherapy interventions. Following medical cannabis use, researchers found significant improvements in sleep quality as measured by the Pittsburgh Sleep Quality Index (p<0.01), and significant improvements in PTSD severity and the intrusiveness, avoidance, and alertness subdomains as measured by the Post-traumatic Diagnostic Scale (p<0.05). Nightmare frequency did not significantly improve (p=0.27).
The treatment-resistant designation matters. This was not a general veteran population — these were individuals for whom other approaches had not produced adequate results. The finding that medical cannabis was associated with measurable improvements in this subgroup represents meaningful signal in a difficult-to-treat cohort.
The Medicinal Versus Recreational Distinction
Across the literature reviewed here, authorized medical use and recreational use show different outcome patterns. The prior studies summarized in Sheehy et al. found recreational cannabis associated with worse PTSD outcomes in some studies; medicinal cannabis associated with improved outcomes. The mechanism is likely not pharmacological — recreational and medical cannabis are chemically similar. It is structural: authorized access brings consistent supply, documented product concentrations, clinical oversight, and a prescribing relationship that shapes how and how much is used.
A 2019 survey of 2,032 authorized patients in Canada’s federal medical cannabis program (Lucas, Baron & Jikomes, Harm Reduction Journal) found that PTSD was among the top conditions for which authorized patients were using cannabis, alongside pain and insomnia. These patients had stable, regulated access — a meaningfully different context than intermittent recreational use.
What the Research Does Not Show
No study here demonstrates that medical cannabis cures or eliminates PTSD. The Nacasch findings are from a cohort of 14 patients without a control group. Sheehy et al.’s own data did not find cannabis use characteristics significantly associated with PTSD severity. The St. Cyr et al. study is a cross-sectional prevalence study, not an outcomes study. The Lucas et al. survey is self-reported and cross-sectional.
The evidence supports further clinical investigation and the clinical relevance of the medicinal versus recreational distinction. It does not support medical cannabis as a first-line PTSD treatment, and no large-scale controlled trial has established it as such.
Access for Canadian Veterans
Veterans Affairs Canada covers the cost of authorized medical cannabis for eligible veterans under its non-insured health benefits program, processed through Medavie Blue Cross. Authorization requires a prescription from a qualified healthcare provider.
For veterans managing PTSD alongside chronic pain, sleep disruption, or both — conditions that frequently co-occur in this population — medical authorization through a licensed Canadian producer represents a regulated access pathway distinct from recreational use.
This article summarizes published peer-reviewed research for informational purposes. It does not constitute medical advice. Medical cannabis requires authorization from a qualified healthcare provider. The research cited represents the findings of independent investigators and does not constitute a health claim about any specific product.
No. Health Canada has not approved cannabis as a treatment for PTSD or any other condition. The research summarized here documents outcomes observed in peer-reviewed studies — it does not constitute a clinical recommendation. Veterans considering medical cannabis should speak with their healthcare provider.
A 2025 cross-sectional study in the Journal of Veterans Studies found that recreational cannabis use was associated with worsening PTSD-related outcomes in some prior studies, while medicinal cannabis — accessed through authorized channels with clinical oversight — was associated with improved outcomes. The distinction appears to reflect access context, product consistency, and the presence of medical supervision rather than the substance itself.
Eligible veterans can receive reimbursement for authorized medical cannabis through Veterans Affairs Canada, administered by Medavie Blue Cross. A valid medical authorization from a licensed healthcare practitioner and registration with a Health Canada licensed producer are required.
A 2019 survey of 2,032 authorized Canadian patients found that chronic pain and mental health conditions — including PTSD, insomnia, and anxiety — were the most commonly reported reasons for authorization. Veterans are significantly represented in Canada’s authorized patient population.
A 2023 study in Frontiers in Psychiatry followed 14 combat veterans with treatment-resistant PTSD — patients who had not responded to prior pharmacological or psychotherapy interventions — and found significant improvements in sleep quality and PTSD severity following medical cannabis use. Authorization decisions are made by the veteran’s healthcare provider based on their individual clinical picture.
References
- Lucas, Baron & Jikomes (2019). Harm Reduction Journal, 16(1): 9. DOI: 10.1186/s12954-019-0278-6
- Nacasch, Avni & Toren (2023). Frontiers in Psychiatry, 13: 1014630. DOI: 10.3389/fpsyt.2022.1014630
- Sheehy, Storey, Rash, Tippin, Parihar & Harris (2025). Journal of Veterans Studies, 11(1): 30–46. DOI: 10.21061/jvs.v11i1.582
- St. Cyr, Nazarov, Le et al. (2023). BMC Psychiatry, 23: 836. DOI: 10.1186/s12888-023-05237-2